Earnings Recaps

Browse reported earnings of the most popular stocks

May 16, 2026 May 15, 2026 May 14, 2026 May 13, 2026 May 12, 2026 May 11, 2026 May 10, 2026 May 9, 2026 May 8, 2026 May 7, 2026 May 6, 2026 May 5, 2026 May 4, 2026 May 3, 2026 May 2, 2026 May 1, 2026 Apr 30, 2026 Apr 29, 2026 Apr 23, 2026 Apr 22, 2026 Apr 21, 2026 Apr 20, 2026 Apr 18, 2026 Apr 17, 2026 Apr 16, 2026 Apr 15, 2026 Apr 14, 2026 Apr 13, 2026 Apr 10, 2026 Apr 9, 2026 Apr 8, 2026 Apr 7, 2026 Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026 Mar 2, 2026 Feb 28, 2026 Feb 27, 2026 Feb 26, 2026 Feb 25, 2026 Feb 24, 2026 Feb 23, 2026 Feb 21, 2026 Feb 20, 2026 Feb 19, 2026 Feb 18, 2026 Feb 17, 2026 Feb 14, 2026 Feb 13, 2026 Feb 12, 2026 Feb 11, 2026 Feb 10, 2026 Feb 9, 2026 Feb 7, 2026 Feb 6, 2026 Feb 5, 2026 Feb 4, 2026 Feb 3, 2026 Feb 2, 2026 Jan 31, 2026 Jan 30, 2026 Jan 29, 2026 Jan 28, 2026 Jan 27, 2026 Jan 26, 2026 Jan 23, 2026 Jan 22, 2026 Jan 21, 2026 Jan 20, 2026 Jan 17, 2026 Jan 16, 2026 Jan 15, 2026 Jan 14, 2026 Jan 9, 2026 Jan 8, 2026 Jan 7, 2026 Jan 6, 2026 Dec 19, 2025 Dec 18, 2025 Dec 17, 2025 Dec 12, 2025 Dec 11, 2025 Dec 10, 2025 Dec 9, 2025 Dec 6, 2025 Dec 5, 2025 Dec 4, 2025 Dec 3, 2025 Dec 2, 2025 Dec 1, 2025 Nov 27, 2025 Nov 26, 2025 Nov 25, 2025 Nov 24, 2025 Nov 23, 2025 Nov 21, 2025 Nov 20, 2025 Nov 19, 2025 Nov 18, 2025 Nov 17, 2025 Nov 15, 2025 Nov 14, 2025 Nov 13, 2025 Nov 12, 2025 Nov 11, 2025 Nov 10, 2025 Nov 9, 2025 Nov 8, 2025 Nov 7, 2025 Nov 6, 2025 Nov 5, 2025 Nov 4, 2025 Nov 1, 2025 Oct 31, 2025 Oct 30, 2025 Oct 29, 2025 Oct 28, 2025 Oct 27, 2025 Oct 25, 2025 Oct 24, 2025 Oct 23, 2025 Oct 22, 2025 Oct 21, 2025 Oct 17, 2025 Oct 16, 2025 Oct 15, 2025 Oct 14, 2025 Oct 9, 2025 Oct 8, 2025 Oct 7, 2025 Sep 25, 2025 Sep 23, 2025 Sep 17, 2025 Sep 16, 2025 Sep 11, 2025 Sep 10, 2025 Sep 9, 2025 Sep 5, 2025 Sep 4, 2025 Sep 3, 2025
24 companies Today

Taiwan Semiconductor Manufacturing Company Limited

2330.TW Q1 2026
Reported: 2026-04-16

TSMC delivered solid first quarter results with an 8.4% sequential revenue increase, driven by strong demand for advanced process nodes, and provided optimistic guidance for Q2 2026, maintaining robust profitability outlook.

Key takeaways
  • Q1 revenue rose to USD 35.9 billion, up 8.4% sequentially, with gross margin expanding to 66.2% amid improved capacity utilization and cost efficiencies.
  • Advanced technologies (7nm and below) accounted for 74% of wafer revenue, with 3nm contributing 25%, highlighting leadership in cutting-edge process adoption.
  • Q2 revenue guidance of USD 39.0–USD 40.2 billion reflects a 10% sequential growth, with gross margins projected at ~66.5%.
  • Capital expenditures for Q1 reached USD 11.1 billion; cash and marketable securities stood at USD 106 billion, supporting ongoing expansion and technology ramp-ups.
  • While geopolitical factors pose potential risks, TSMC’s diversified supply chain and energy resilience strategies aim to mitigate near-term disruptions.

Abbott Laboratories

ABT Q1 2026
Reported: 2026-04-16

Abbott delivered aligned first-quarter results with steady earnings and achieved a key strategic milestone with the acquisition of Exact Sciences, enhancing its diagnostics leadership and growth prospects.

Key takeaways
  • Adjusted EPS of $1.15 met guidance despite headwinds from early financing costs and a weaker respiratory season.
  • Completed the Exact Sciences acquisition, adding ~$3 billion in expected 2026 sales and accelerating long-term growth trajectory.
  • Diagnostics sales grew 2%, with Core Lab up 3%, while Molecular Diagnostics declined 10% due to weaker respiratory testing demand.
  • Cancer Diagnostics posted 13% growth driven by strong international performance and Cologuard.
  • Medical Devices revenue increased 8.5%, led by robust cardiovascular product sales, supported by pipeline advancements and clinical trial initiatives.

Barry Callebaut AG

BARN.SW Q2 2026
Reported: 2026-04-16

Barry Callebaut delivered a challenging first half, impacted by volume declines and operational disruptions, but has begun laying the groundwork for recovery through strategic refocus and cost savings.

Key takeaways
  • Volume declines and supply chain issues amid industry volatility led to lower sales and market share erosion.
  • The Next Level program delivered CHF 150 million in savings but contributed to capacity constraints and quality incidents.
  • Leadership’s initial assessment emphasizes the need to simplify operations, prioritize core fundamentals, and accelerate execution of the Focus for Growth plan.
  • Cocoa prices declined sharply, providing a potential tailwind for improving margins and supporting demand recovery.
  • The company remains confident in its market position and long-term growth potential, centered on strong customer relationships and key categories.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...